- Asia
- Automobile
- Bangladesh
- Banking
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Company Act
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Media
- Digital Right Management
- Educational Conferences/ Seminar
- Fashion Law
- FERs
- Foreign Law
- Gaming Industry
- GDPR
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Khadi Industries
- labour Law
- Legal Issues
- Licensing
- Live-in relationships
- Lok Sabha Bill
- Media & Entertainment Law
- Member of Parliament
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Online Gaming
- Patent Act
- Patent Commercialisation
- Patent Fess
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Protection of SMEs
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stamp Duty
- Stock Exchange
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
Why Protecting Patents in India is Giving Hard Time to Drug Patent Holders
Introduction A lot has been discussed on the Novartis ruling indicating much higher standards of patentability under Indian law under section 3d. The ruling decided that any new form of known compound (in medicine) would be patentable only if there is enhanced ‘therapeutic efficacy’ over the known compound. Post Novartis ruling, a couple of patent … Continue reading Why Protecting Patents in India is Giving Hard Time to Drug Patent Holders
Read more »